Oneskin secures USD 20M investment from Prelude Growth Partners to fuel growth
The funding marks a significant step for the brand to advance scientific innovation in the anti-ageing skincare industry and make its technology more accessible to consumers.
USA – OneSkin, an American skincare brand, has successfully secured USD 20 million in total funding by closing its Series A investment round, led by Prelude Growth Partners, a growth capital firm based in New York.
This capital funding will enable OneSkin to accelerate its growth and expand its pioneering research and product development in skin longevity, focusing on science-led topical treatments that target ageing at the cellular level.
The Series A round, which was oversubscribed, is led by Selva Ventures with additional support from Plus Capital, Unilever Ventures, Able Partners, and previous investors SOSV and Meta Planet.
The company aims to redefine skin health by not only enhancing aesthetics but also improving skin’s functional role as the body’s largest organ, thereby impacting overall health and longevity.
In addition, OneSkin plans to deepen research initiatives, develop innovative new formulas, and extend its market reach through enhanced human capital and new sales channels.
Dr. Alessandra Zonari, co-founder and CSO of Oneskin, stated, “This investment will allow us to deepen our commitment to be the best in class in delivering efficacious peptides to modulate ageing at the cellular level, ensuring that our science-backed solutions deliver measurable results in promoting healthier skin.”
“We are dedicated to advancing the future of skin health with the most advanced longevity research and innovation.”
Founded in 2016 by four Brazilian PhD scientists, OneSkin has emerged as a category leader with its patented peptide OS-01, clinically proven to reverse skin’s biological ageing by preventing the buildup of senescent cells, a key driver of skin ageing.
OneSkin offers a science-driven range of topical skincare products designed to promote skin longevity and reduce signs of ageing.
Their hero ingredient, OS-01, is a proprietary peptide clinically proven to target cellular senescence, helping improve skin texture, elasticity, and tone.
Key products include OS-01 FACE, a daily serum-moisturiser hybrid; OS-01 EYE, formulated for delicate under-eye skin; and OS-01 FACE SPF 30+, which combines sun protection with anti-ageing benefits.
In addition, they also offer supporting products like the PREP Cleanser, lip SPF, and curated bundles for streamlined skin health routines.
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
